Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of its Treatment with Sorafenib.

Trial Profile

Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of its Treatment with Sorafenib.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Mar 2017

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions
  • Acronyms GIDEON
  • Sponsors Bayer
  • Most Recent Events

    • 01 Mar 2017 Results of evaluation of sorafenib in Chinese patients (n=338) published in the Tumour Biology
    • 19 Oct 2016 Results (n=512) of a pooled analysis from the Italian subgroup of GIDEON and from STELLA study assessing safety and efficacy in clinical practice, presented at the 24th United European Gastroenterology Week
    • 03 Jun 2014 Interim results (n=1115) presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top